Last updated on May 2018

A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia


Brief description of study

The study will examine the safety profile of SGN-CD123A. The study will test increasing doses of SGN-CD123A given every 3 weeks to patients.

Detailed Study Description

This study is designed to evaluate the safety, tolerability, and preliminary estimate of antitumor activity of SGN-CD123A. The study will be conducted in 2 parts:

  1. Part A is the dose-escalation portion of the trial, designed to identify the maximum tolerated dose (MTD) of SGN-CD123A
  2. Part B is the dose-expansion portion of the trial, designed to evaluate SGN-CD123A in patients with differing CD123 expression levels

Dose-escalation in Part A will be conducted using a 3+3 study design. Patients with CD123-detectable AML will be enrolled in cohorts at escalating doses of study drug and will receive up to 2 induction cycles of SGN-CD123A treatment at an assigned dose level in 3-week cycles.

After completion of dose-escalation, patients will be enrolled in Part B of the study. Patients enrolled in Part B will receive up to 2 induction cycles of SGN-CD123A treatment at a dose level and frequency determined by results in Part A.

For both Part A and Part B, a third induction cycle may be permitted with the approval of the study medical monitor. If a patient achieves a complete remission or complete remission with incomplete hematologic recovery, optional post-remission cycles of SGN-CD123A may be administered.

Clinical Study Identifier: NCT02848248

Contact Investigators or Research Sites near you

Start Over

Harry Erba

University of Alabama at Birmingham
Birmingham, AL United States

Guido Marcucci

City of Hope National Medical Center
Duarte, CA United States

Daniel Pollyea

University of Colorado Hospital / University of Colorado
Aurora, CO United States

Amir Fathi

Massachusetts General Hospital
Boston, MA United States

Karen Seiter

Hudson Valley Hematology and Oncology Associates/New York Medical College
Hawthorne, NY United States

Farhad Ravandi-Kashani

MD Anderson Cancer Center / University of Texas
Houston, TX United States

Roland Walter

Fred Hutchinson Cancer Research Center
Seattle, WA United States